Core Viewpoint - Surmodics, Inc. reported a wider-than-expected adjusted loss per share and lower-than-expected revenues for the second quarter of fiscal 2025, indicating challenges in its Medical Device segment and overall financial performance [1][14]. Revenue Performance - Surmodics generated revenues of $28.1 million in the fiscal second quarter, a decrease of 12.1% year over year, missing the Zacks Consensus Estimate by 8.7% [2]. - Total revenues included $0.3 million from SurVeil drug-coated balloon (DCB) license fees, down from $1.1 million in the same quarter of the previous year, attributed to lower expenses related to the TRANSCEND clinical trial [3]. - Product sales were $14.9 million, down 17.2% from the prior-year quarter, and royalties and license fees totaled $9.9 million, down 13.2% [7]. Segment Analysis - The Medical Device segment reported sales of $20.7 million, a decline of 16.6% year over year, with revenues excluding SurVeil DCB license fees decreasing 14% [5]. - In Vitro Diagnostics (IVD) sales improved by 3.4% year over year to $7.4 million, driven by favorable order timing, although this was offset by a decline in microarray slide/surface revenues [6]. Margin and Expenses - Gross profit decreased by 18.5% year over year to $20.3 million, with gross margin contracting 566 basis points to 72.1% [9]. - Selling, general & administrative expenses increased by 14.9% year over year to $15 million, while research and development expenses declined by 18.2% to $8.4 million [9]. Financial Position - Surmodics ended the second quarter with cash and cash equivalents of $29.2 million, a slight decrease from $30.1 million at the end of the previous quarter [11]. - Total long-term debt was $29.63 million, marginally up from $29.59 million in the prior quarter [11]. Fiscal Guidance - The company expects total revenues for fiscal 2025 to be in the range of $114 million to $117 million, reflecting a decrease of 10-7% compared to fiscal 2024 [12]. - Surmodics anticipates a decrease of $3.6 million in SurVeil DCB license fee revenues and a $7 million decrease in SurVeil DCB product revenues for fiscal 2025 [13]. Market Reaction - Shares of Surmodics fell nearly 9.4% at the end of the trading session following the earnings report [4].

Company Overview - PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors [4] - The company has two subsidiaries: Lucid Diagnostics, which focuses on cancer prevention diagnostics, and Veris Health, which enhances personalized cancer care through remote patient monitoring [4] Upcoming Conference Call - PAVmed will host a business update conference call and webcast on May 15, 2025, at 8:30 AM ET [1] - The call will feature Lishan Aklog, M.D., providing an overview of the company's operations and growth strategy, and Dennis McGrath discussing the first quarter 2025 financial results [1] Access Information - The webcast will be available on the investor relations section of the company's website [2] - U.S.-based callers can join the conference call by dialing 1-800-836-8184, while international listeners should dial 1-646-357-8785 [2] Replay Availability - A replay of the conference call will be available for 30 days on the investor relations section of the company's website [3]

Core Points - Aimfinity Investment Corp. I (AIMA) will be delisted from Nasdaq and will begin trading on OTC Markets under new tickers on May 5, 2025 [1] - AIMA's business combination with Docter Inc. remains on track despite the venue change, with both parties committed to securing Nasdaq listing approval for the combined entity [2] - AIMA has extended the deadline to complete the business combination to May 28, 2025, by depositing $55,823.80 into its trust account [3][4] Company Information - Aimfinity Investment Corp. I is a special purpose acquisition company (SPAC) focused on merging with high-growth potential businesses [5] - Docter Inc. is a health technology company that develops innovative health monitoring solutions to improve global healthcare accessibility and efficiency [6] Transaction Details - AIMA entered into a merger agreement with Docter on October 13, 2023, involving a reincorporation merger and an acquisition merger [7] - The proxy statement/prospectus related to the proposed business combination has been mailed to AIMA's shareholders as of February 25, 2025 [12]

Industry Overview - The Medical sector is experiencing a continued recovery in sales, with earnings increasing year over year by 4.7% on 9.4% higher revenues, although inflationary pressures and supply chain challenges persist [1][2] - The first-quarter earnings for the Medical sector are expected to improve by 35%, while sales are projected to increase by 7.8%, compared to the previous quarter's earnings growth of 13.4% and revenue growth of 9.4% [3] Medical Device Industry Insights - The medical device industry began 2025 with robust growth, driven by sustained demand for advanced healthcare solutions and the normalization of elective procedures, with the global market projected to reach $1.3 trillion by 2029 [4] - Challenges such as semiconductor shortages and workforce shortages in AI and robotics are impacting production and innovation [5] - Trade tensions, particularly U.S.-China tariffs, have increased operational costs for medical device manufacturers, with 75% of U.S.-marketed medical devices manufactured abroad [6] Company Performance Expectations - Becton Dickinson is expected to report strong second-quarter results, with a projected revenue growth of 16.3% year over year in its Medical division, although a slight dip of 1.3% is anticipated in the Life Sciences segment [8] - Cardinal Health is expected to show steady performance in its Pharmaceutical and Specialty Solutions segment, supported by strategic acquisitions, despite the impact of a key customer contract expiration [10] - Baxter International is projected to report moderate growth, with an estimated 6.6% sales growth in its Medical Products & Therapies segment, aided by operational recovery [11] - DexCom's outlook remains promising, with a full-year revenue guidance of $4.6 billion, driven by expanded U.S. prescriber coverage and strong international performance [12] - Stryker Corporation is expected to show strong growth across multiple segments, with projected U.S. and international sales reaching $4.74 billion and $1.59 billion, respectively [13]

Core Insights - ONWARD Medical N.V. has filed its Annual Report for the fiscal year ended December 31, 2024, with the Dutch Authority for the Financial Markets (AFM) [1] - The company has also released its 2024 Sustainability Report and received a silver medal from EcoVadis for business sustainability ratings [2] - CEO Dave Marver highlighted that 2024 was transformative for ONWARD, emphasizing the company's mission to restore movement and independence for individuals with spinal cord injuries [2] Company Overview - ONWARD Medical is focused on creating therapies aimed at restoring movement, function, and independence for people with spinal cord injuries and other movement disabilities [3] - The company has developed ARC Therapy, which has received ten Breakthrough Device Designations from the US FDA, and its ARC-EX System is cleared for commercial sale in the US [3] - ONWARD is also working on an investigational implantable system called ARC-IM, which may include a brain-computer interface [3] Locations and Listings - The company is headquartered in the Netherlands, with a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts [4] - ONWARD Medical is listed on Euronext Paris, Brussels, and Amsterdam under the ticker ONWD, and its US ADRs can be traded on OTCQX under the ticker ONWRY [4]

~ Strong start to the year with 1Q25 financial results ~ ~ Reiterating 2025 sales and adjusted operating income outlook; raising adjusted EPS outlook ~ PLANO, Texas, April 24, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced results for the three months ended March 28, 2025. First Quarter 2025 Highlights (compared to First Quarter 2024, except as noted) "Integer started the year off strong with first quarter 2025 sales growing at 7% year-over-year as we continue to execute o ...

Core Insights - Neuronetics, Inc. plans to release its first quarter 2025 financial and operating results on May 6, 2025, prior to market open [1] - A conference call will be held at 8:30 a.m. Eastern Time on the same day to discuss the results [1][2] Company Overview - Neuronetics, Inc. focuses on improving the quality of life for patients with neurohealth disorders through innovative medical technology [3] - The company is a leader in neuroscience, offering the NeuroStar Advanced Therapy, a non-drug, noninvasive treatment for mental health conditions [3] - NeuroStar is indicated for treating depressive episodes and reducing anxiety symptoms in adults with Major Depressive Disorder (MDD) who have not responded to previous antidepressant treatments [3] - The therapy is also FDA-cleared for use as an adjunct treatment for adults with obsessive-compulsive disorder and for adolescents aged 15-21 with MDD [3] - Over 7.1 million NeuroStar treatments have been delivered, establishing it as the leading Transcranial Magnetic Stimulation (TMS) treatment for MDD in adults [3]

Core Points - Enovis Corporation announced the appointment of Damien McDonald as CEO, effective May 12, 2025, succeeding Matt Trerotola who will retire [1][3] - The company expects first quarter revenues to be between $555 million and $563 million, with adjusted EBITDA projected to be between $97 million and $100 million [1][6] Leadership Transition - Sharon Wienbar, Lead Independent Director, expressed enthusiasm for McDonald's appointment, highlighting his strong track record in the medical technology sector [2] - McDonald has over 35 years of experience in the medical device industry, previously serving as CEO of LivaNova, where he improved growth, profitability, and shareholder value [2][3] - Following Trerotola's retirement, Wienbar will assume the role of independent Chair of the Board [3] Company Overview - Enovis Corporation is focused on developing clinically differentiated medical technology solutions aimed at improving patient outcomes [4] - The company emphasizes a culture of continuous improvement and innovation, with a diverse range of products and services in orthopedics and beyond [4]

Core Viewpoint - Polyrizon Ltd. has successfully closed a private placement raising approximately $17.0 million through the sale of Ordinary Shares and/or pre-funded and investor warrants at a price of $0.48 per Ordinary Unit [1][3]. Group 1: Offering Details - The offering included the sale of 35,416,667 Ordinary Units, each comprising one Ordinary Share or Pre-Funded Warrant and one Series A Warrant to purchase one Ordinary Share [2]. - The initial exercise price for each Series A Warrant is set at $1.20 per Ordinary Share, with a term of 30 months, and is subject to shareholder approval [2]. - The Pre-Funded Warrants can be exercised at any time following shareholder approval [2]. Group 2: Use of Proceeds - The net proceeds from the offering, along with existing cash, are intended for general corporate purposes and working capital [3]. Group 3: Company Overview - Polyrizon is a development-stage biotech company focused on innovative intranasal hydrogels that create a barrier against viruses and allergens in the nasal cavity [6]. - The company's proprietary technology, Capture and Contain TM, aims to function as a "biological mask" and is being further developed for drug delivery [6]. - Polyrizon is also working on an earlier-stage technology, Trap and Target ™, for nasal delivery of active pharmaceutical ingredients [6].

Company Appoints Medical Device and Healthcare Industry Veteran with 20 Years of ExperienceEXTON, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- Lungpacer Medical today announced the appointment of Kevin Kearney as Chief Commercial Officer (CCO). Kearney brings over 20 years of commercial leadership, business development, and strategic sales operations experience in the medical device and healthcare industries. His appointment marks a significant milestone as the company expands its footprint and accelerates its m ...